198 related articles for article (PubMed ID: 37490805)
1. Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer.
Hoffman SLV; Mixdorf JC; Kwon O; Johnson TR; Makvandi M; Lee H; Aluicio-Sarduy E; Barnhart TE; Jeffery JJ; Patankar MS; Engle JW; Bednarz BP; Ellison PA
Nucl Med Biol; 2023; 122-123():108368. PubMed ID: 37490805
[TBL] [Abstract][Full Text] [Related]
2. Panitumumab-DOTA-
Facca VJ; Cai Z; Gopal NEK; Reilly RM
Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
[TBL] [Abstract][Full Text] [Related]
3. PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response.
Riad A; Gitto SB; Lee H; Winters HD; Martorano PM; Hsieh CJ; Xu K; Omran DK; Powell DJ; Mach RH; Makvandi M
Molecules; 2020 Dec; 25(24):. PubMed ID: 33352773
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer.
Sreekumar S; Zhou D; Mpoy C; Schenk E; Scott J; Arbeit JM; Xu J; Rogers BE
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834491
[TBL] [Abstract][Full Text] [Related]
5. [
Chan CY; Chen Z; Guibbal F; Dias G; Destro G; O'Neill E; Veal M; Lau D; Mosley M; Wilson TC; Gouverneur V; Cornelissen B
J Nucl Med; 2023 Dec; 64(12):1965-1971. PubMed ID: 37770109
[TBL] [Abstract][Full Text] [Related]
6. A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy.
Destro G; Chen Z; Chan CY; Fraser C; Dias G; Mosley M; Guibbal F; Gouverneur V; Cornelissen B
Nucl Med Biol; 2023; 116-117():108312. PubMed ID: 36621256
[TBL] [Abstract][Full Text] [Related]
7. PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma.
Lee H; Riad A; Martorano P; Mansfield A; Samanta M; Batra V; Mach RH; Maris JM; Pryma DA; Makvandi M
J Nucl Med; 2020 Jun; 61(6):850-856. PubMed ID: 31676730
[TBL] [Abstract][Full Text] [Related]
8. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.
Makvandi M; Pantel A; Schwartz L; Schubert E; Xu K; Hsieh CJ; Hou C; Kim H; Weng CC; Winters H; Doot R; Farwell MD; Pryma DA; Greenberg RA; Mankoff DA; Simpkins F; Mach RH; Lin LL
J Clin Invest; 2018 May; 128(5):2116-2126. PubMed ID: 29509546
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of PEGylated ⁶⁴Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT.
Petersen AL; Henriksen JR; Binderup T; Elema DR; Rasmussen PH; Hag AM; Kjær A; Andresen TL
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):941-952. PubMed ID: 26646780
[TBL] [Abstract][Full Text] [Related]
10. Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.
Dasa SSK; Diakova G; Suzuki R; Mills AM; Gutknecht MF; Klibanov AL; Slack-Davis JK; Kelly KA
Theranostics; 2018; 8(10):2782-2798. PubMed ID: 29774075
[TBL] [Abstract][Full Text] [Related]
11. PARP-1 Expression Quantified by [
Sander Effron S; Makvandi M; Lin L; Xu K; Li S; Lee H; Hou C; Pryma DA; Koch C; Mach RH
Cancer Biother Radiopharm; 2017 Feb; 32(1):9-15. PubMed ID: 28118040
[TBL] [Abstract][Full Text] [Related]
12. PARP-targeted Meitner-Auger Electron-emitting Radiopharmaceutical for Radioligand Therapy.
Tan KV
Radiol Imaging Cancer; 2023 Nov; 5(6):e239022. PubMed ID: 37975803
[No Abstract] [Full Text] [Related]
13. Design, Synthesis, and Evaluation of [
Zheng W; Huang Y; Xie Y; Yang T; Cheng X; Chen H; Li C; Jiang Z; Yu Z; Li Z; Zhang L; Yuan L; Liu Y; Liang Y; Wu Z
Mol Pharm; 2024 May; 21(5):2606-2621. PubMed ID: 38606716
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
[TBL] [Abstract][Full Text] [Related]
15. PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models.
Wilson T; Pirovano G; Xiao G; Samuels Z; Roberts S; Viray T; Guru N; Zanzonico P; Gollub M; Pillarsetty NVK; Reiner T; Bargonetti J
Mol Pharm; 2021 Sep; 18(9):3418-3428. PubMed ID: 34318678
[TBL] [Abstract][Full Text] [Related]
16. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo.
Lahorte CM; Bacher K; Burvenich I; Coene ED; Cuvelier C; De Potter C; Thierens H; Van de Wiele C; Dierckx RA; Slegers G
J Nucl Med; 2004 Jun; 45(6):1065-73. PubMed ID: 15181142
[TBL] [Abstract][Full Text] [Related]
18. Preliminary evaluation of a novel
Zhou D; Xu J; Mpoy C; Chu W; Kim SH; Li H; Rogers BE; Katzenellenbogen JA
Nucl Med Biol; 2018 Nov; 66():26-31. PubMed ID: 30195072
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.
Besemer AE; Grudzinski JJ; Weichert JP; Hall LT; Bednarz BP
Cancer Biother Radiopharm; 2019 Feb; 34(1):13-23. PubMed ID: 30351218
[TBL] [Abstract][Full Text] [Related]
20. Targeted Brain Tumor Radiotherapy Using an Auger Emitter.
Pirovano G; Jannetti SA; Carter LM; Sadique A; Kossatz S; Guru N; Demétrio De Souza França P; Maeda M; Zeglis BM; Lewis JS; Humm JL; Reiner T
Clin Cancer Res; 2020 Jun; 26(12):2871-2881. PubMed ID: 32066626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
